Affinivax is developing a next-generation approach in vaccine technologies. The Centers for Disease Control and Prevention estimates that 4% of patients will contract a healthcare-associated infection each year due to antimicrobial resistance. Affinivax is addressing antimicrobial resistance with their patented technology platform called the Multiple Antigen Presentation System (MAPSTM) to develop several vaccines. The MAPSTM platform simplifies vaccine design and selects for key immunogenic epitopes to induce robust immune protection in a single vaccine.
The novel vaccines designed by Affinivax are to be tested against challenging infectious diseases. AFX3772, their lead vaccine candidate for Streptococcus pneumoniae, is expected to be tested in Phase 3 clinical trials this year.